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Abstract
Background
Blocking the PD-1 pathway induces immune-related adverse events (irAEs) which often
involve the thyroid gland (thyroid irAEs). Clinical features of a thyroid irAE including its
predictability and relationship to prognosis remain to be elucidated.
Methods
Two hundred consecutive patients treated with nivolumab at Kyoto University Hospital
between September 1, 2014 and August 31, 2017 were included in a retrospective cohort
study. We systematically determined and classified subclinical and overt thyroid irAEs
based on data collected of serum free T4 and TSH levels. Baseline characteristics and
detailed clinical data were analyzed, and analyses of overall survival (OS) excluded patients
censored within 1 month from the first administration of nivolumab.
Results
Sixty-seven patients (33.5%) developed thyroid irAEs and these were divided into a subclini-
cal thyroid irAE group (n = 40, 20.0%) and an overt thyroid irAE group (n = 27, 13.5%).
Patients with thyroid uptake of FDG-PET before treatment showed high incidences of overt
thyroid irAE (adjusted odds ratio 14.48; 95% confidence interval [CI] 3.12–67.19), while the
same relationship was not seen with subclinical thyroid irAE. Regarding the total cohort, the
thyroid irAE (+) group had a significantly longer median OS than the thyroid irAE (−) group
(16.1 versus 13.6 months, hazard ratio [HR] 0.61; 95% CI 0.39–0.93). In 112 non-excluded
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patients with lung cancer, the thyroid irAE (+) group similarly had a longer median OS than
the thyroid irAE (−) group (not reached versus 14.2 months, HR 0.51; 95% CI 0.27–0.92).
However, this observation was not seen in 41 non-excluded patients with malignant mela-
noma (12.0 versus 18.3 months, HR 1.54; 95% CI 0.67–3.43).
Conclusions
By thyroid uptake of FDG-PET, overt thyroid irAEs could be predicted before nivolumab
therapy. Thyroid irAEs related to good prognosis in lung cancer but might be inconclusive in
malignant melanoma.
Introduction
Immune checkpoint inhibitors have been applied to a variety of malignancies [1]. Monoclonal
antibodies against cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), programmed cell
death-1 (PD-1), and programmed death-ligand 1 have been approved. Immune-related
adverse events (irAEs) are commonly caused by these inhibitors and involve several endo-
crine-related organs. For example, hypophysitis with ipilimumab, an anti-CTLA-4 antibody;
and ACTH deficiency, type 1 diabetes, and thyroid dysfunction with nivolumab and pembroli-
zumab, anti-PD-1 antibodies, have been reported [2].
We previously performed a case-series study of irAEs involving the thyroid gland (thyroid
irAEs) induced by nivolumab [3]. Our observation that nivolumab caused a transient and
rapid course of thyrotoxicosis and subsequent persistent hypothyroidism seemed to be distinc-
tive compared to conventional painless thyroiditis. Studies regarding pembrolizumab revealed
high incidences of thyroid irAEs [4, 5].
From the other perspective, there were several reports that the occurrence of irAEs was
related to good prognosis [6–12]. However, a few of those focused on individual irAEs: skin
irAEs in malignant melanoma [6], and pneumonia in non-small cell lung cancer (NSCLC)
[12]. These two findings might be reasonable because the primary site of the cancer and the
organs affected by the irAE were the same. Meanwhile, a curious relationship between thyroid
irAEs and good prognosis in NSCLC was reported [7, 9], but further validation is needed
because sample sizes of these reports were small (51 [7] and 58 patients [9]).
The present study aimed to gain further understanding of a thyroid irAE using a retrospec-
tive cohort of patients who received nivolumab therapy. In particular, we tried to predict
thyroid irAE development by parameters available before treatment, and to validate the rela-
tionship between thyroid irAEs and good prognosis, including but not limited to lung cancer.
If both predictive factors and favorable effects on prognosis of thyroid irAEs are determined,
the indication of PD-1 pathway blockade therapy could be optimized.
Patients and methods
Patients
A retrospective cohort study was performed using the medical records of patients at Kyoto
University Hospital. We selected consecutive patients who were started nivolumab therapy
between September 1, 2014 and August 31, 2017, and provided them with opportunity to opt
out using our website instead of obtaining informed consent. All data of them were collected
and fully anonymized in the secured electronic medical record system, and then the input
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dataset was transferred and imported to analysis software. This study was approved by the
Institutional Review Board and Ethics Committee of the Kyoto University Graduate School of
Medicine (approval number, R1400), and was conducted in accordance with the principles of
the Declaration of Helsinki.
Assays
Thyroid function tests which consisted of serum free T3 (fT3), free T4 (fT4), and TSH levels
were performed using electrochemiluminescent immunoassay (Elecsys FT3 II kit, Elecsys FT4
kit, and Elecsys TSH kit, respectively; Roche Diagnostics, Mannheim, Germany); the reference
ranges were 2.33–4.00 pg/mL, 0.880–1.620 ng/dL, and 0.500–5.000 μIU/mL, respectively. Lev-
els of anti-thyroperoxidase antibodies (TPOAbs) and anti-thyroglobulin antibodies (TgAbs)
were also measured using electrochemiluminescent immunoassay (Elecsys Anti-TPO kit and
Elecsys Anti-Tg kit, respectively; Roche Diagnostics). Thyroid uptake of FDG-PET was
defined as diffusely increased FDG uptake in the thyroid gland.
Assessments of irAE
Thyroid irAEs were determined by the data of serum fT4 and TSH levels for 6 months from
first administration of nivolumab. We excluded patients for which abnormal values for these
measurements were not a result of nivolumab therapy according to the following criteria: 1)
data of thyroid function tests were unavailable; 2) serum TSH levels were normalized during
the follow-up period; 3) total thyroidectomy was previously performed; 4) serum TSH levels
did not exceed 10.000 μIU/mL in patients with mild subclinical hypothyroidism (defined as
TSH < 10.000 μIU/mL); 5) serum fT4 levels did not fall below the reference range in patients
with moderate subclinical hypothyroidism (defined as TSH� 10.000 μIU/mL); and 6) low
TSH values were only observed during glucocorticoid therapy. Subsequently, if neither serum
fT4 nor TSH levels were normal, patients were classified into an overt thyroid irAE group; oth-
ers were classified into a subclinical thyroid irAE group.
Non-thyroid irAEs were characterized as adverse events involving organs other than the
thyroid gland that required intravenous or oral glucocorticoid therapy for resolution. Best
overall responses and progression-free survival (PFS) were determined using the assessment of
the physicians based on RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1
[13]. The follow-up periods were at least 6 months and as long as 2 years: patients without
death were censored at 2 years since their first administration of nivolumab or at data lock
time in February 28, 2018. Seventeen patients were otherwise censored because of hospital
transfer or treatment interruption.
Statistical analysis
The number of treated patients during the study period determined the sample size. It was suf-
ficient to detect an hazard ratio (HR) for overall survival (OS) of 0.45 with 80% power at the
5% level of significance, assuming that incidence of thyroid irAE was approximately 15% [4, 5,
7] and median OS was 40 months in patients without thyroid irAE [7].
Data of continuous variables were expressed as medians (interquartile range). Comparisons
of parameters between two groups were analyzed by Mann-Whitney U test or Pearson’s chi-
square test, and those among more than two groups were by Kruskal-Wallis test or Pearson’s
chi-square test corrected by Bonferroni’s method. Odds ratios were calculated and adjusted by
logistic regression model. Landmark cohorts were used for ad hoc analyses of OS in lung can-
cer subgroup [14]. OS and PFS were expressed by the Kaplan-Meier method, and comparisons
of them were analyzed by Cox proportional hazards model between two groups and by
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generalized Wilcoxon test corrected by Bonferroni’s method among three groups. Cox propor-
tional hazards model was also used for multivariate analyses of OS. JMP pro version 11.3.0
(SAS institute Inc., Cary, NC) was used for all statistical analyses. A P-value of< 0.05 was con-
sidered statistically significant.
Results
Incidence and classification of thyroid irAE
Characteristics of the 200 recruited patients are presented in S1 Table. Prior chemotherapy
had been performed in all 118 patients with lung cancer, but only in 16 of 42 patients (38.1%)
with malignant melanoma. No patients had received prior immune checkpoint blockade ther-
apies. The patients received nivolumab at 2 mg/kg every 3 weeks (for malignant melanoma) or
3 mg/kg every 2 weeks (for lung cancer and other malignancies). The median duration of nivo-
lumab therapy was 69 (28–163) days. Thyroid function were tested every 3 weeks in patients
with malignant melanoma and every 4 weeks in patients with lung cancer and other malignan-
cies during nivolumab therapy as a general rule in Kyoto University Hospital. The compliance
rates of thyroid function tests were 88.6%, 93.8%, and 90.1% in malignant melanoma, lung
cancer, and other malignancies, respectively. TPOAbs and TgAbs were tested in 17 patients
(8.5%) and FDG-PET scans were performed in 111 patients (55.5%). Other parameters were
available from all patients.
We checked all of the data of the thyroid function tests of these patients and systematically
classified them as shown in Fig 1. The thyroid irAE (+) group (n = 67, 33.5%) was divided into
the subclinical thyroid irAE group (n = 40, 20.0%) and the overt thyroid irAE group (n = 27,
13.5%).
The subclinical thyroid irAE group consisted of 22 patients with normal fT4 and high TSH
levels, 7 with high fT4 and normal TSH, 6 with low fT4 and normal TSH, and 5 with normal
fT4 and low TSH. Of the 6 patients with low fT4 and normal TSH levels, 4 patients were
accompanied by marked decreases in fT3 levels (1.01, 1.32, 1.41, and 1.54 pg/mL), and other 2
patients only showed slight low fT4 levels (0.878 and 0.867 ng/dL). These did not suggest
development of central hypothyroidism due to hypophysitis as non-thyroid irAEs. Of the 27
patients with overt thyroid irAEs, transient thyrotoxicosis was observed in 17 patients (63.0%);
11 of these 17 patients (64.7%) developed subsequent hypothyroidism.
High fT3 values were observed in 18 patients; 13 patients also presented high fT4 values
and other 5 patients did not present any abnormal TSH values. High TSH values were
observed in 48 of 125 patients (38.4%) with low fT3 values and in 24 of 36 patients (66.7%)
with low fT4 values. Thus, fT4-based determination was more specific both for thyrotoxicosis
and hypothyroidism.
Prediction of thyroid irAE
We performed subgroup analyses of the subclinical thyroid irAE group and the overt thyroid
irAE group compared to the thyroid irAE (−) group (Table 1 and S2 Table). Of parameters
available before nivolumab therapy, the overt thyroid irAE group showed significant differ-
ences in sex, thyroid uptake of FDG-PET, and serum TSH levels (Table 1). In multiple logistic
regression model with these three parameters, thyroid uptake of FDG-PET was only associated
with overt thyroid irAE development (Adjusted odds ratio [OR] 14.48; 95% confidence inter-
val [CI] 3.12–67.19, P< 0.001) (Table 2). There were no significant differences in plasma glu-
cose levels at FDG administration (P = 0.540): the medians were 115 mg/dL (106–132), 119
mg/dL (107–141), and 111 mg/dL (101–121) in the thyroid irAE (−) group, the subclinical thy-
roid irAE group, and the overt thyroid irAE group, respectively.
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Clinical features of overt thyroid irAE
Detailed clinical data of 27 patients with overt thyroid irAEs are presented in S3 Table (17
patients with thyrotoxicosis) and S4 Table (10 patients without thyrotoxicosis). In 17 patients,
TPOAbs and TgAbs were tested at the point of thyroid dysfunction development; seven
patients were double positive, 5 were double negative, and 5 were exclusively positive for
TgAbs, while no patients were exclusively positive for TPOAbs.
Fig 1. A flowchart for determination of immune-related adverse events involving the thyroid gland (thyroid irAEs).
Determination and classifications were based on data of thyroid function tests.
https://doi.org/10.1371/journal.pone.0216954.g001
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Thyrotoxicosis frequently developed within 4 weeks from the first administration of nivolu-
mab; 4 patients developed thyrotoxicosis at 2 weeks, 3 at 3 weeks, and 3 at 4 weeks. Subsequent
hypothyroidism was more frequently observed in patients that developed thyrotoxicosis within
4 weeks (8 of 10 patients, 80%) than in patients that developed thyrotoxicosis after 4 weeks (3
of 7 patients, 43%). We plotted all of the data (S1 Fig) and the medians (Fig 2) of the thyroid
function tests and levothyroxine doses of the 17 patients with thyrotoxicosis to understand the
time course. Thyrotoxicosis tended to occur transiently from 2 to 6 weeks, and subsequent
hypothyroidism tended to develop from 12 weeks; then, persistent levothyroxine replacement
had been performed.
Table 1. Characteristics of patients with subclinical and overt thyroid irAEs and comparisons to those without thyroid irAEs.
Thyroid irAE (−) Thyroid irAE (+)
n = 133 Subclinical p Overt p
n = 40 n = 27
Age (years) 67 (60–73) 69 (58–75) 0.701 67 (60–73) 0.958
Gender (n) 0.420 0.022
Male 94 (70.7%) 27 (67.5%) 13 (48.2%)
Female 39 (29.3%) 13 (32.5%) 14 (51.8%)
Primary sites (n) 0.286 0.409
Lung cancer 77 (57.9%) 29 (72.5%) 12 (44.5%)
Malignant melanoma 28 (21.05%) 6 (15.0%) 8 (29.6%)
Others 28 (21.05%) 5 (12.5%) 7 (25.9%)
Results before nivolumab therapy
Positive TPOAb (n) 0 (tested in 7) (0.0%) 1 (tested in 4) (25.0%) NA 3 (tested in 6) (50.0%) NA
Positive TgAb (n) 0 (tested in 7) (0.0%) 1 (tested in 4) (25.0%) NA 5 (tested in 6) (83.3%) NA
Thyroid uptake of FDG-PET (n) 3 (tested in 71) (4.2%) 1 (tested in 25) (4.0%) 1.000 7 (tested in 15) (46.7%) < 0.001
Thyroid function
free T3 (pg/mL) 2.57 (2.20–2.89) 2.49 (2.25–2.83) 0.684 2.59 (2.18–2.82) 0.895
free T4 (ng/dL) 1.250 (1.100–1.380) 1.270 (1.100–1.360) 0.979 1.160 (0.946–1.350) 0.184
TSH (μIU/mL) 2.260 (1.353–4.443) 2.580 (0.935–4.430) 0.940 3.620 (1.870–7.310) 0.014
Data of continuous variable were expressed as medians (interquartile range). Statistical analyses were performed against thyroid irAE (–) group.
We did not perform statistical analysis of TPOAb and TgAb results because the numbers of missing values were large.
n: number of subjects, irAE: immune-related adverse event, NA: not available
https://doi.org/10.1371/journal.pone.0216954.t001
Table 2. Odds ratio for overt thyroid irAE development.
OR/Adjusted OR (95% CI) p
Univariate analysis
Sex (Female > Male) 2.60 (0.86–7.85) 0.090
Thyroid uptake of FDG-PET 19.91 (4.79–82.79) < 0.001
TSH > 2.5 μIU/mL 3.06 (0.91–10.28) 0.071
Multivariate analysis
Sex (Female > Male) 1.62 (0.41–6.37) 0.493
Thyroid uptake of FDG-PET 14.48 (3.12–67.19) < 0.001
TSH > 2.5 μIU/mL 2.68 (0.67–10.67) 0.162
Statistical analysis was performed using logistic regression model.
Results of thyroid uptake of FDG-PET and TSH were obtained before nivolumab therapy.
OR: odds ratio, CI: confidence interval
https://doi.org/10.1371/journal.pone.0216954.t002
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Furthermore, relevance of thyroid uptake of FDG-PET to the clinical features of thyroid
irAE was investigated. We could obtain simultaneous results of 7 patients on TPOAb, TgAb,
and FDG-PET by including data after the first administration of nivolumab (S3 and S4
Tables), and find the 6 patients with thyroid uptake of FDG-PET were all positive for TgAb
(Case No: T4, T6, T8, T11, T17, and H2). Meanwhile, 6 of 7 patients who presented the maxi-
mum standardized uptake value (SUVmax)� 4.0 at thyroid developed severe hypothyroidism
(defined as TSH > 100 μIU/mL) (Case No: T4, T6, T11, T17, H2, H3, and H7).
Prognosis of patients with thyroid irAEs
To prevent immortal time bias, we excluded patients censored within 1 month from the first
administration of nivolumab for OS analyses, as the early onset was the representative course
of thyroid irAE. The results of cohorts including all patients are shown in S2 Fig. The numbers
of excluded patients with deaths were 9, 6, and 1, and those with progressive diseases were 25,
15, and 5 in the total cohort, the lung cancer subgroup, and the malignant melanoma sub-
group, respectively.
We observed that the median OS was significantly longer in the thyroid irAE (+) group
than in the thyroid irAE (−) group (16.1 versus 13.6 months, hazard ratio [HR] 0.61; 95% CI
0.39–0.93, P = 0.022, Fig 3A). When the total cohort divided according to overt and subclinical
thyroid irAE, the median OS was significantly longer in the overt thyroid irAE group than in
the thyroid irAE (−) group (P = 0.033, Fig 3B), but the subclinical thyroid irAE group was not
(P = 0.348, Fig 3B). There was no difference between the overt and the subclinical thyroid irAE
groups (P = 0.459, Fig 3B).
An analysis of 112 non-excluded patients with lung cancer showed similar results; the
median OS was significantly longer in the thyroid irAE (+) group than in the thyroid irAE (−)
group (not reached versus 14.2 months, HR 0.51; 95% CI 0.27–0.92, P = 0.025, Fig 3C). How-
ever, in 41 non-excluded patients with malignant melanoma, this observation was not seen
(12.0 versus 18.3 months in the thyroid irAE (+) group and the thyroid irAE (−) group, respec-
tively, HR 1.54; 95% CI 0.67–3.43, P = 0.301, Fig 3D). In Cox proportional hazards models in
Fig 2. The representative clinical course of overt thyroid irAE. Regarding 17 patients with overt thyroid irAEs and thyrotoxicosis, the
medians of the results of thyroid function tests and doses of levothyroxine replacement were plotted. For clarity, the values of 3, 9, 15, and 21
weeks in patients with malignant melanoma were integrated into those of 4, 10, 16, and 22 weeks, respectively.
https://doi.org/10.1371/journal.pone.0216954.g002
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lung cancer, there were no significant differences in prior radiation therapy, histology (adeno-
carcinoma or squamous cell carcinoma), and prior epidermal growth factor receptor-tyrosine
kinase inhibitor therapy (S5 Table).
PFS was analyzed in a similar manner. The median PFS was significantly longer in the thy-
roid irAE (+) group than in the thyroid irAE (−) group (4.9 versus 2.9 months, HR 0.66; 95%
CI 0.46–0.95, P = 0.023, Fig 4A). There were no significant differences in either of the overt
and the subclinical thyroid irAE group, compared to the thyroid irAE (−) group (P = 0.123
and 0.226, respectively, Fig 4B). In 103 non-excluded patients with lung cancer, the median
PFS was significantly longer in the thyroid irAE (+) group than in the thyroid irAE (−) group
(5.8 versus 2.3 months, HR 0.55 95% CI 0.33–0.88, P = 0.012, Fig 4C), but in 37 non-excluded
patients with malignant melanoma, no significant difference was seen as well as OS (3.3 versus
4.1 months in the thyroid irAE (+) group and the thyroid irAE (−) group, respectively, HR
0.94; 95% CI 0.41–2.00, P = 0.885, Fig 4D).
Thyroid irAE seemed to relate to good prognosis in lung cancer, but immortal time bias
still remained because we determined thyroid irAEs by the data for 6 months from first
Fig 3. Kaplan-Meier curves of overall survival according to thyroid irAEs. Patients censored within 1 month from the first administration
of nivolumab were excluded from each cohort. (A) Results in the total cohort; (B) results of comparisons between the overt thyroid irAE group
and the subclinical thyroid irAE group in the total cohort; (C) results in the cohort of lung cancer; (D) results in the cohort of malignant
melanoma. HR, hazard ratio; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0216954.g003
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administration of nivolumab. We planned ad hoc landmark analyses regarding OS of the lung
cancer subgroup: censored patients were excluded and thyroid irAEs were determined by data
up to the landmarks of 1 month, 2 months, 3 months, and 6 months. Statistical power was cal-
culated at the 5% level of significance to detect effect size of 30%: this calculation was based on
the results regarding Fig 3 that OS probabilities at 12 months in the lung cancer cohort were
71.4% (n = 35) and 42.3% (n = 52) in the thyroid irAE (+) group and the thyroid irAE (−)
group, respectively. In 1-month landmark analysis, the power was 94.9%, assuming 12 patients
developed thyroid irAE within 1 month and 75 patients did not, as the case series of overt thy-
roid irAE (S3 and S4 Tables): in 6-month landmark analysis, the power was 94.8%, assuming
26 patients developed thyroid irAE and 39 patients did not, as 29 of 112 patients (25.9%) were
intended to be excluded. Thus, the ad hoc analyses had sufficient power.
Kaplan-Meier curves of OS in the ad hoc landmark analyses are shown in S3 Fig. We com-
pared OS probability at 12 months after the first administration of nivolumab because Cox
proportional hazards model was not applicable in 1-month, 2-month, and 3-month landmark
cohorts. The thyroid irAE (+) group showed significant higher OS probability than the thyroid
Fig 4. Kaplan-Meier curves of progression-free survival according to thyroid irAEs. Patients censored within 1 month from the first
administration of nivolumab were excluded from each cohort. (A) Results in the total cohort; (B) results of comparisons between the overt
thyroid irAE group and the subclinical thyroid irAE group in the total cohort; (C) results in the cohort of lung cancer; (D) results in the cohort
of malignant melanoma.
https://doi.org/10.1371/journal.pone.0216954.g004
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irAE (−) group in the 1-month landmark analysis (76.5% versus 48.6%, P = 0.038) and the
2-month landmark analysis (73.1% versus 50.0%, P = 0.049). Significant changes were not seen
in the 3-month landmark analysis (75.0% versus 57.8%, P = 0.135) and the 6-month landmark
analysis (83.3% versus 64.7%, P = 0.092). Meanwhile, we verified thyroid uptake of FDG-PET
was significantly associated with overt thyroid irAE development within 1 month, 2 months,
and 3 months (S6 Table) as well as 6 months (Table 1).
To verify whether this discrepancy was limited to thyroid irAEs, we analyzed 4 subgroups;
thyroid irAE(−) and non-thyroid irAE(−) as a no irAE group (n = 47 in lung cancer, n = 18 in
malignant melanoma); thyroid irAE(+) and non-thyroid irAE(−) as a thyroid irAE group
(n = 27, n = 10); thyroid irAE(−) and non-thyroid irAE(+) as a non-thyroid irAE group (n = 5,
n = 5); and thyroid irAE(+) and non-thyroid irAE(+) as a both irAE group (n = 8, n = 3).
Detailed characteristics are presented in S7 Table and Kaplan-Meier curves of OS probability
are in S4 Fig. In the lung cancer subgroup, the thyroid irAE group showed significant higher
OS probability at 12 months after the first administration of nivolumab than no irAE group
(70.4% versus 40.4%, P = 0.013), while the non-thyroid irAE group did not (60.0% vs 40.4%,
P = 0.400). Conversely, in the malignant melanoma subgroup, the non-thyroid irAE group
showed significant higher OS probability (100.0% vs 50.0%, P = 0.043), while the thyroid irAE
group did not (50.0% vs 50.0%, P = 1.000).
Discussion
We conducted this retrospective cohort study to obtain clinically useful findings of thyroid
irAEs. Overt thyroid irAEs frequently developed in patients positive for thyroid uptake of
FDG-PET, while subclinical thyroid irAEs did not. In representative patients with overt thy-
roid irAEs, transient thyrotoxicosis promptly occurred within 2 to 6 weeks after the first
administration of nivolumab, and subsequent hypothyroidism requiring persistent levothyrox-
ine replacement from 12 weeks. The finding with the most clinical influence was the relation-
ship between thyroid irAEs and good prognosis. However, this relationship was significant
and independent of prior therapy in the lung cancer subgroup, but not significant in the malig-
nant melanoma subgroup.
The present study provided the first data of a large cohort regarding nivolumab-induced
thyroid irAE. In addition, we could evaluate exclusive effects of PD-1 pathway blockade ther-
apy because our cohort did not include any patients who had received prior immune check-
point blockade therapies such as ipilimumab, unlike two previous studies [4, 5]. Our results
showed a higher incidence of thyroid irAE than previous reports regarding pembrolizumab;
17 of 99 patients (17.2%) [4], 13 of 93 patients (14.0%) [5], and 10 of 48 patients (20.8%) [7].
This might have been caused by our systematic determination that could even detect subclini-
cal thyroid irAEs, as the incidence of overt thyroid irAE was similar to the above reports [4, 5].
Likewise, the incidence of thyroid irAE in the present study was higher than that of a meta-
analysis of clinical trials of anti-PD-1 and anti-PD-L1 antibodies; hypothyroidism was 6.07%
and thyrotoxicosis was 2.82% [15]. This discrepancy between a real-world setting and clinical
trials suggested that the difference of definitions and screening methods was a matter to be
considered. On the other hand, we confirmed that the most frequent course of thyroid irAE is
a transient thyrotoxicosis with subsequent hypothyroidism, as seen in our previous case series
[3] and the previous report [4].
It was reported that TPOAbs and TgAbs were often positive in patients with thyroid irAEs
[9, 16, 17]. Based on a report that only positive results for TPOAbs were significantly associ-
ated with hypothyroidism [18], the TgAb test has not been recommended for management of
hypothyroidism [19]. However, as there were 5 patients exclusively positive for TgAb and no
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patients exclusively positive for TPOAb in our case series, TgAb rather than TPOAb seemed to
be related to overt thyroid irAEs. The number of examined patients was small, so further pro-
spective studies are needed. There was another interesting observation that 5 patients were
double negative for TPOAbs and TgAbs, which provided a hypothesis that thyroid irAEs are
not always caused by these antibodies, but by antibodies for unknown antigens or unknown
mechanisms unrelated to humoral immunity.
It is known that thyroid uptake of FDG-PET could be positive at the period of thyroid
irAE development [4, 16]. We additionally confirmed that thyroid uptake of FDG-PET before
treatment increased the risk of overt thyroid irAE development. It also needs to be noted that
relative high thyroid uptake of FDG-PET, defined as SUVmax� 4.0 in the present study,
could suggest development of severe subsequent hypothyroidism. If high thyroid uptake of
FDG-PET is seen, we might have to follow more closely to diagnose and treat hypothyroidism
without delay.
From other perspective, all examinable patients with thyroid uptake of FDG-PET were pos-
itive for TgAb, but positive results of TPOAb were limited to a part of them. Thyroid uptake
of FDG-PET has been considered to be a result of thyroiditis, while it is not associated with
TPOAb levels [20]. The present observation also supports the notion that the significance of
TgAb in thyroid irAEs is worth examining.
In addition, thyroid uptake of FDG-PET, as a predictive factor of thyroid irAEs that is avail-
able before treatment, has become important because thyroid irAEs have been revealed to be a
prognostic factor. Our landmark analyses using the larger cohort provided further evidences
of this interesting relationship that was previously suggested by two previous reports that non-
landmark analyses were performed using the smaller cohorts [7, 9]. At this point, the multiple
landmark analyses supported that thyroid irAE development within 2 months had relevant
association with good prognosis. However, further careful examinations are needed for confir-
mation because these analyses were just ad hoc. Overt thyroid irAEs are thought to be more
meaningful because they are predictable by thyroid uptake of FDG-PET and their relationships
to prolonged OS and PFS have been confirmed. Subclinical thyroid irAEs are needed for fur-
ther examinations as they have not been established as a prognostic factor and their prediction
by surveillance before treatment is unable at this point.
Our analyses involving multiple primary sites revealed a very important observation; thy-
roid irAEs were a possible prognostic factor for lung cancer, but might not for malignant mela-
noma. It should be noted that the evidences on thyroid irAE from previous reports [7, 9] and
the present study could be applied only to lung cancer. Although the number of patients was
small, non-thyroid irAEs significantly related to good prognosis in malignant melanoma.
There remains a possibility that thyroid irAEs has the weak relationship with prognosis com-
pared to non-thyroid irAEs in malignant melanoma. Other malignancies certainly need indi-
vidual examinations.
We suggest a hypothesis that target antigens common to the lung and the thyroid gland
exist, to explain this crucial finding. The evidence that irAEs are likely to develop in the same
organs with primary sites might support this hypothesis: pneumonia is common in lung can-
cer, while skin irAEs are common in malignant melanoma [6]. If thyroid irAEs are caused by
antibodies recognizing antigens common to the lung, immune responses to lung cancer are
expected.
There were several limitations due to the retrospective design. The number of patients
tested with TPOAbs and TgAbs was small, and stages of malignancies and their treatments
prior to or post nivolumab were heterogeneous. However, evidence in this field is still limited
because difficulties in collecting prospective data have arisen due to the rarity of thyroid irAEs
Incidence, features, and prognosis of thyroid irAE
PLOS ONE | https://doi.org/10.1371/journal.pone.0216954 May 14, 2019 11 / 14
and ethical considerations. Our findings could contribute to clinical settings and provide
novel hypotheses.
In conclusion, overt thyroid irAEs have a stronger impact than subclinical thyroid irAEs
because they could be predicted before treatment by thyroid uptake of FDG-PET. Develop-
ment of thyroid irAEs related to good prognosis in the total cohort and the lung cancer sub-
group, but might not in the malignant melanoma subgroup. Considering the predictive
factors of overt thyroid irAEs could be a promising strategy for PD-1 pathway blockade
therapy.
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S1 Fig. Individual results of 17 patients with thyrotoxicosis. (A)(B)(C) Line graphs of results
of thyroid function tests of 17 patients with overt immune-related adverse events involving the
thyroid gland and thyrotoxicosis. (D) A box plot of doses of levothyroxine (LT4) replacement
for these 17 patients. Each box represents the interquartile range. The horizontal line in each
box represents the median. The ends of the vertical lines represent the minimum and maxi-
mum values.
(TIF)
S2 Fig. Kaplan-Meier curves of overall survival according to thyroid irAEs in cohorts
including all patients. (A) Results in the total cohort; (B) results of comparisons between the
overt thyroid irAE group and the subclinical thyroid irAE group in the total cohort; (C) results
in the lung cancer subgroup; (D) results in the malignant melanoma subgroup. HR, hazard
ratio; CI, confidence interval.
(TIF)
S3 Fig. Kaplan-Meier curves of overall survival in ad hoc landmark analyses of lung cancer.
Thyroid irAEs were determined by data up to each landmark and patients censored within the
landmarks were excluded. (A) Results in the 1-month landmark cohort, (B) results in the
2-month landmark cohort, (C) results in the 3-month landmark cohort, and (D) results in the
6-month landmark cohort. Statistical analyses were performed for overall survival probabilities
at 12 months after the first administration of nivolumab. irAE, immune-related adverse event.
(TIF)
S4 Fig. Kaplan-Meier curves of overall survival according to thyroid irAEs and non-thy-
roid irAEs. Patients censored within 1 month from the first administration of nivolumab were
excluded from each cohort. (A) Results in the cohort of lung cancer; (B) results in the cohort
of malignant melanoma. Statistical analyses were performed for overall survival probabilities
at 12 months after the first administration of nivolumab against no irAE group. irAE,
immune-related adverse event.
(TIF)
S1 Table. Patient characteristics of a total cohort and subgroups according to primary
sites.
(XLSX)
S2 Table. Additional characteristics of patients with subclinical and overt thyroid irAEs.
(XLSX)
S3 Table. Detailed clinical data of patients with overt thyroid irAEs who developed thyro-
toxicosis.
(XLSX)
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S4 Table. Detailed clinical data of patients with overt thyroid irAEs who did not develop
thyrotoxicosis.
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S5 Table. Cox proportional hazards models of overall survival in lung cancer.
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S6 Table. Characteristics of patients with thyroid irAEs and comparisons to those without
thyroid irAEs in ad hoc landmark analyses.
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